Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GTC’s ATryn receives FDA orphan designation
ATryn is GTC’s recombinant form of human antithrombin, a protein with anticoagulant and anti-inflammatory properties that is normally present in human plasma. Orphan drug designation provides GTC with
ATryn is GTC’s recombinant form of human antithrombin, a protein with anticoagulant and anti-inflammatory properties that is normally present in human plasma. Orphan drug designation provides GTC with
Two central experiments were undertaken; firstly human acute myeloid leukemia (AML) stem cells were treated with the drug, 7G3, and then injected into the mice, which were compared
The data demonstrated that omacetaxine reduced the number of leukemic stem cells in the bone marrow by more than 80% in an animal model of CML (mice with
Based on the FDA’s request for additional data and analyses, the company now expects that approval of its Andara OFS system for the treatment of acute spinal cord
Inovio will receive this milestone payment for its contribution to the collaboration, which has so far demonstrated the high level of gene delivery and expression that is thought
The co-primary endpoints for these studies will evaluate the differences between treatments in mean percent weight loss and in the percentage of subjects achieving weight loss of 5%
Carigent will apply the proceeds to further develop its nanotechnology platform, improve laboratory production capabilities and core expertise to support partnerships with pharmaceutical and biotechnology companies, and advance
Patient recruitment has started and several additional clinical centers are expected to start recruiting within the next few weeks. The trial remains on track for completion in 2008.
Phentermine hydrochloride (HCl) is indicated for the short-term management of obesity. The company expects to commence marketing this product immediately. Arthur Bedrosian, president and CEO of Lannett, said:
As a subset analysis of a larger double-blind trial, the study comparing Euflexxa and Synvisc demonstrated that an intra-articular hyaluronic acid (IA-HA) treatment for knee osteoarthritis (OA) is